.jpg "TrovaGene (NASDAQ: TROV)")
Noble Financial analyst Ahu Demir maintained a Buy rating on TrovaGene (TROV) yesterday. The company’s shares closed yesterday at $0.67, close to its 52-week low of $0.47.
Demir has an average return of 19.6% when recommending TrovaGene.
According to TipRanks.com, Demir is ranked #3096 out of 5144 analysts.
Currently, the analyst consensus on TrovaGene is a Moderate Buy with an average price target of $3, representing a 351.1% upside. In a report issued on January 30, Maxim Group also maintained a Buy rating on the stock with a $3 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.70 and a one-year low of $0.47. Currently, TrovaGene has an average volume of 370.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. Its focuses on developing PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor.
